These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22693419)

  • 21. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost.
    Fechtner RD; Harasymowycz P; Nixon DR; Vold SD; Zaman F; Williams JM; Hollander DA
    Clin Ophthalmol; 2011; 5():945-53. PubMed ID: 21792284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
    Larsson LI
    Acta Ophthalmol Scand; 2001 Apr; 79(2):125-8. PubMed ID: 11284748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study.
    Okumichi H; Kiuchi Y; Baba T; Kanamoto T; Naito T; Nakakura S; Tabuchi H; Nii H; Sueoka C; Sugimoto Y
    Clin Ophthalmol; 2017; 11():1175-1181. PubMed ID: 28790802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.
    Kashiwagi K
    Jpn J Ophthalmol; 2012 Jul; 56(4):339-45. PubMed ID: 22581454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
    Martinez A; Sanchez M
    Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients.
    Sakai H; Shinjyo S; Nakamura Y; Nakamura Y; Ishikawa S; Sawaguchi S
    J Ocul Pharmacol Ther; 2005 Dec; 21(6):483-9. PubMed ID: 16386090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
    Susanna R; Sheu WP;
    Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination.
    Sellem E; Rouland JF; Baudouin C; Bron A; Denis P; Nordmann JP; Renard JP
    BMC Ophthalmol; 2010 Mar; 10():10. PubMed ID: 20346127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
    Larsson LI
    J Glaucoma; 2001 Apr; 10(2):109-14. PubMed ID: 11316092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.
    Özyol E; Özyol P
    J Glaucoma; 2016 Feb; 25(2):135-9. PubMed ID: 25264990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.
    Zhao JL; Ge J; Li XX; Li YM; Sheng YH; Sun NX; Sun XH; Yao K; Zhong Z;
    BMC Ophthalmol; 2011 Aug; 11():23. PubMed ID: 21851642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.